DOCSLIB.ORG

Immunological Goals for Respiratory Syncytial Virus Vaccine Development Graham 59

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Immunological Goals for Respiratory Syncytial Virus Vaccine Development Graham 59 Available online at www.sciencedirect.com ScienceDirect Immunological goals for respiratory syncytial virus vaccine development Barney S Graham Defining the immunological goals for respiratory syncytial virus mice, cotton rats, and African green monkeys, they are all (RSV) vaccination requires understanding of RSV biology and semi-permissive. Even chimpanzees from which the virus tropism, mechanisms of cell-to-cell spread and immunity, was first identified as chimpanzee coryza agent [2] are not epidemiology, and transmission dynamics. The immunological known to acquire or transmit RSV in the wild. In part, this goalsforaparticularvaccinewould beproduct-specificbasedon is related to the extreme sensitivity RSV has to innate antigen selection, delivery approach, and target population. immunity mediated by type 1 interferons (IFN). RSV has 0 There are many ways to achieve immunity against RSV infection devoted the first two 5 genes to making the non- involving innate and adaptive responses, humoral, and cellular structural proteins NS1 and NS2. These two proteins effector mechanisms, and mucosal and systemic responses. have multiple mechanisms to inhibit both the induction Both protective and pathological immune response patterns and effector mechanisms of IFN and are highly species- have been demonstrated in animal models and humans. In this specific [3]. This may explain why it has been so difficult short commentary, the entire information matrix that may inform to establish animal models of RSV that can be infected the design of particular vaccine candidates cannot be fully nasally with a low dose and reliable spread from the upper reviewed, but the rationale behind the major vaccine approaches to lower airway. It may also explain why only a small in key target populations will be discussed. fraction of individuals develop severe disease. Roughly 20% of first-time infections in infants result in symptom- Address atic lower respiratory tract infections, about 10% of those Vaccine Research Center, National Institute of Allergy and Infectious (2% overall) require hospitalization. In the frail elderly, Diseases, NIH, Bethesda, MD 20892, USA about 5–10% are infected each year, about 1–2% have Corresponding author: Graham, Barney S ([email protected]) significant medically attended disease and only about 0.1% require hospitalization. Since infection is so ubiqui- tous, the public health burden imposed by RSV is large Current Opinion in Immunology 2019, 59:57–64 and justifies the development of vaccines for prevention. This review comes from a themed issue on Vaccines Edited by Shane Crotty Vaccine antigens For a complete overview see the Issue and the Editorial Apart from using live-attenuated virus vaccines that express Available online 25th April 2019 all proteins, the major antigenic targets for RSV vaccine https://doi.org/10.1016/j.coi.2019.03.005 development are the surface proteins (Fusion glycoprotein (F), the G glycoprotein, and the Small Hydrophobic protein 0952-7915/Published by Elsevier Ltd. (SH)) and internal proteins (nucleoprotein (N), matrix protein (M), and nonstructural proteins like M2). The primary goal for vaccines based on surface proteins is to elicit protective antibody responses. However, there are different mechanisms of antibody-mediated protection for each of these targets. Neutralizing activity is the primary Introduction endpoint for F-based vaccines, and F antigenicity is con- RSV is an orthopneumovirus in the Pneumoviridae family. It formation-dependent. The prefusion conformation of F is a single-stranded, negative-sense RNA virus that encodes (pre-F) has highly neutralization-sensitive antigenic sites 11 known proteins from ten open reading frames[1]. Although that do not exist on the rearranged postfusion conformation RSV can infect most adherent cell lines in vitro, human RSV is oftheprotein(post-F) [4].AntibodiestoGmayinducesome highly adapted to infect select cells in the human airway in neutralizing activity, but one form of G is secreted and vivo. The primary targets of infection are the polarized, known to have immunomodulatory effects [5–7], so anti- differentiated, ciliated epithelial cells and the type 1 alveolar bodies that block this activity could also reduce virulence pneumocyte. Virus buds from cells as filamentous projections and improve immune responses during subsequent infec- from cholesterol-rich lipid microdomains at the apical surface, tions in addition to neutralizing virus [8]. SH is a pentameric and its life cycle resides in the superficial epithelium and the ion channel present on the viral membrane. Antibodies to airway, and it rarely becomes systemic. SH do not neutralize RSV, but can mediate Antibody Dependent Cellular Cytotoxicity (ADCC) and perhaps There is no known zoonotic reservoir of RSV and while other Fc effector functions [9]. Antibodies to internal pro- animal models for human RSV have been developed in teins are non-neutralizing, but internal proteins are www.sciencedirect.com Current Opinion in Immunology 2019, 59:57–64 58 Vaccines included in vaccines to induce T-cell responses and can be Antibody-mediated neutralization used alone [10] or in combination with surface proteins [11]. F and G are the primary targets for neutralizing antibodies against RSV. F is a class I fusion protein which means after endoproteolytic cleavage and assembly, it is a trimer Immunological basis of vaccine-enhanced of heterodimers in a metastable, pre-triggered illness (what to avoid) conformation poised to interact with host cell membranes The primary goal for RSV vaccine development is pro- (Figure 1). When pre-F is triggered by interaction with tecting antigen-naı¨ve infants less than six months of age, host cells, the hydrophobic fusion peptide at the N- and effective immunization of the frail elderly is an terminus of F1 anchors the heptad repeat 1 (HR1) important secondary goal. Immunization of other popula- adjacent to the host cell membrane. The attraction of tions like toddlers, school-age children, or healthy adults HR1 to HR2 adjacent to the transmembrane domain pulls would be done largely to prevent transmission and indi- the host and viral membranes together leading to mem- rectly protect other susceptible populations. It may also brane fusion and opening of a pore that allows the viral be beneficial to immunize individuals preparing for allo- genome to enter the host cell. This rearrangement is genic bone marrow transplantation or lung transplantation unidirectional and leaves the F protein in antiparallel because of their susceptibility to often lethal nosocomial six-helix bundle postfusion conformation. F is, therefore, RSV infections [12]. required for viral entry making it an important target for neutralizing antibodies. There are five major neutralizing The immunization goals for antigen-naı¨ve infants are sites (Ø, II, III, IV, and V) on the surface of the pre-F complicated by the history of vaccine-enhanced respira- glycoprotein, and the most neutralization sensitive are at tory disease (ERD) that occurred following immunization the apex (Ø and V). Sites I, II, and IV are preserved on the with a formalin-inactivated virus (FI-RSV) formulated surfaces of post-F. Sites II and IV are neutralization- with alum in children in the 1960s. This is the 50-year sensitive, but site I antibodies are typically non- anniversary of the publications in 1969 describing four neutralizing and generally have higher binding affinity age cohorts of children given three doses of the vaccine for post-F than pre-F. Stabilizing F in the pre-F confor- and the outcomes following infection in the 1966–1967 mation results in an immunogen that induces about 80- winter season [13–15,16 ]. Within the youngest age fold higher neutralization activity in Rhesus macaques cohort, vaccinated children had higher rates of hospitali- than a post-F immunogen [25,26 ]. The G glycoprotein zation (80%) and death (10%) than unvaccinated children is another surface protein that is targeted by neutralizing [16 ]. Subsequent studies of immune response patterns in antibodies. The G glycoprotein has two overlapping trial subjects and animal models over the last five decades neutralizing epitopes in the central conserved domain have identified two major immunological features of the around the cysteine noose [27]. Antibodies to the central FI-RSV ERD. One is that antibody with poor functional conserved domain not only neutralize RSV but can reduce activity was induced. Both the neutralizing and fusion- ERD in murine models [28]. inhibition activities were weak while binding antibody measured by ELISA and complement fixation titers were Generation of high potency neutralizing antibodies is a substantial [16 ,17,18]. This led to immune complex primary immunological goal for RSV vaccines for both deposition and complement activation in the small air- young infants and the elderly. There is evidence from ways [19]. Additionally, a Th2-biased CD4 T cell maternal-infant pairs that neutralizing activity in cord response occurred after infection causing eosinophils in blood correlates with protection from severe disease in the peribronchiolar infiltrates and neutrophilic alveolitis infants [29], and passively administered polyclonal immu- in the lung histopathology of children who died. A Th2- noglobulin with high neutralizing activity can protect biased response has been reproduced in mice [20] and high-risk premature infants from severe disease [30]. alveolitis is a feature of FI-RSV immunization in cotton Palivizumab is a licensed
Load more

Recommended publications
  • Increased Interseasonal Respiratory Syncytial Virus (RSV) Activity in Parts of the Southern United States
    This is an official CDC Health Advisory Distributed via Health Alert Network June 10, 2021 3:00 PM 10490-CAD-06-10-2021-RSV Increased Interseasonal Respiratory Syncytial Virus (RSV) Activity in Parts of the Southern United States Summary The Centers for Disease Control and Prevention (CDC) is issuing this health advisory to notify clinicians and caregivers about increased interseasonal respiratory syncytial virus (RSV) activity across parts of the Southern United States. Due to this increased activity, CDC encourages broader testing for RSV among patients presenting with acute respiratory illness who test negative for SARS-CoV-2, the virus that causes COVID-19. RSV can be associated with severe disease in young children and older adults. This health advisory also serves as a reminder to healthcare personnel, childcare providers, and staff of long-term care facilities to avoid reporting to work while acutely ill – even if they test negative for SARS-CoV-2. Background RSV is an RNA virus of the genus Orthopneumovirus, family Pneumoviridae, primarily spread via respiratory droplets when a person coughs or sneezes, and through direct contact with a contaminated surface. RSV is the most common cause of bronchiolitis and pneumonia in children under one year of age in the United States. Infants, young children, and older adults with chronic medical conditions are at risk of severe disease from RSV infection. Each year in the United States, RSV leads to on average approximately 58,000 hospitalizations1 with 100-500 deaths among children younger than 5 years old2 and 177,000 hospitalizations with 14,000 deaths among adults aged 65 years or older.3 In the United States, RSV infections occur primarily during the fall and winter cold and flu season.
    [Show full text]
  • Isolation and Characterization of Clinical RSV Isolates in Belgium During the Winters of 2016–2018
    viruses Article Isolation and Characterization of Clinical RSV Isolates in Belgium during the Winters of 2016–2018 Winke Van der Gucht 1, Kim Stobbelaar 1,2, Matthias Govaerts 1 , Thomas Mangodt 2, Cyril Barbezange 3 , Annelies Leemans 1, Benedicte De Winter 4, Steven Van Gucht 3 , Guy Caljon 1, Louis Maes 1 , Jozef De Dooy 4,5, Philippe Jorens 4,5, Annemieke Smet 4 , Paul Cos 1, Stijn Verhulst 2,4 and Peter L. Delputte 1,* 1 Laboratory of Microbiology, Parasitology and Hygiene, and Infla-Med Centre of Excellence, University of Antwerp (UA), Universiteitsplein 1 S.7, 2610 Antwerp, Belgium; [email protected] (W.V.d.G.); [email protected] (K.S.); [email protected] (M.G.); [email protected] (A.L.); [email protected] (G.C.); [email protected] (L.M.); [email protected] (P.C.) 2 Pediatrics Department, Antwerp University Hospital (UZA), Wilrijkstraat 10, 2650 Edegem, Belgium; [email protected] (T.M.); [email protected] (S.V.) 3 Sciensano, Rue Juliette Wytsmanstraat 14, 1050 Brussels, Belgium; [email protected] (C.B.); [email protected] (S.V.G.) 4 Laboratory of Experimental Medicine and Pediatrics, University of Antwerp (UA), Univeristeitsplein 1 T.3, 2610 Antwerp, Belgium; [email protected] (B.D.W.); [email protected] (J.D.D.); [email protected] (P.J.); [email protected] (A.S.) 5 Pediatric intensive care unit, Antwerp University Hospital (UZA), Wilrijkstraat 10, 2650 Edegem, Belgium * Correspondence: [email protected]; Tel.: +32-3-265-26-25 Received: 29 July 2019; Accepted: 4 November 2019; Published: 6 November 2019 Abstract: Respiratory Syncytial Virus (RSV) is a very important viral pathogen in children, immunocompromised and cardiopulmonary diseased patients and the elderly.
    [Show full text]
  • Phylogenetic Evidence of a Novel Lineage of Canine Pneumovirus And
    Piewbang and Techangamsuwan BMC Veterinary Research (2019) 15:300 https://doi.org/10.1186/s12917-019-2035-1 RESEARCH ARTICLE Open Access Phylogenetic evidence of a novel lineage of canine pneumovirus and a naturally recombinant strain isolated from dogs with respiratory illness in Thailand Chutchai Piewbang1 and Somporn Techangamsuwan1,2* Abstract Background: Canine pneumovirus (CPV) is a pathogen that causes respiratory disease in dogs, and recent outbreaks in shelters in America and Europe have been reported. However, based on published data and documents, the identification of CPV and its variant in clinically symptomatic individual dogs in Thailand through Asia is limited. Therefore, the aims of this study were to determine the emergence of CPV and to consequently establish the genetic characterization and phylogenetic analysis of the CPV strains from 209 dogs showing respiratory distress in Thailand. Results: This study identified and described the full-length CPV genome from three strains, designated herein as CPV_ CP13 TH/2015, CPV_CP82 TH/2016 and CPV_SR1 TH/2016, that were isolated from six dogs out of 209 dogs (2.9%) with respiratory illness in Thailand. Phylogenetic analysis suggested that these three Thai CPV strains (CPV TH strains) belong to the CPV subgroup A and form a novel lineage; proposed as the Asian prototype. Specific mutations in the deduced amino acids of these CPV TH strains were found in the G/glycoprotein sequence, suggesting potential substitution sites for subtype classification. Results of intragenic recombination analysis revealed that CPV_CP82 TH/2016 is a recombinant strain, where the recombination event occurred in the L gene with the Italian prototype CPV Bari/100–12 as the putative major parent.
    [Show full text]
  • Respiratory Infections and Coinfections: Geographical and Population Patterns Norvell Perezbusta-Lara, Rocío Tirado-Mendoza* and Javier R
    GACETA MÉDICA DE MÉXICO ORIGINAL ARTICLE Respiratory infections and coinfections: geographical and population patterns Norvell Perezbusta-Lara, Rocío Tirado-Mendoza* and Javier R. Ambrosio-Hernández Universidad Nacional Autónoma de México, Faculty of Medicine, Department of Microbiology y Parasitology, Mexico City, Mexico Abstract Introduction: Acute respiratory infections are the second cause of mortality in children younger than five years, with 150.7 million episodes per year. Human orthopneumovirus (hOPV) and metapneumovirus (hMPV) are the first and second causes of bronchiolitis; type 2 human orthorubulavirus (hORUV) has been associated with pneumonia in immunocompromised patients. Objective: To define hOPV, hMPV and hORUV geographical distribution and circulation patterns. Method: An observational, prospective cross-sectional pilot study was carried out. Two-hundred viral strains obtained from pediatric patients were genotyped by endpoint reverse transcription polymerase chain reaction (RT-PCR). Results: One-hundred and eighty-six positive samples were typed: 84 hOPV, 43 hMPV, two hORUV and 57 co-infection specimens. Geographical distribution was plotted. hMPV, hOPV, and hORUV cumulative incidences were 0.215, 0.42, and 0.01, respectively. Cumulative incidence of hMPV-hORUV and hMPV-hOPV coinfection was 0.015 and 0.23; for hOPV-hMPV-hORUV, 0.035; and for hORUV-hOPV, 0.005. The largest num- ber of positive cases of circulating or co-circulating viruses occurred between January and March. Conclusions: This study successfully identified circulation and geographical distribution patterns of the different viruses, as well as of viral co-infections. KEY WORDS: Acute respiratory infections. Human respiratory viruses. Viral coinfections. Circulation patterns. Infecciones y coinfecciones respiratorias: patrón geográfico y de circulación poblacional Resumen Introducción: Las infecciones respiratorias agudas constituyen la segunda causa de mortalidad en los niños menores de cinco años, con 150.7 millones de episodios anuales.
    [Show full text]
  • Synergism and Antagonism of Bacterial-Viral Co-Infection in the Upper Respiratory Tract
    bioRxiv preprint doi: https://doi.org/10.1101/2020.11.11.378794; this version posted November 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Synergism and antagonism of bacterial-viral co-infection in the upper respiratory tract Sam Manna1,2,3, Julie McAuley3, Jonathan Jacobson1, Cattram D. Nguyen1,2, Md Ashik Ullah4, Victoria Williamson1, E. Kim Mulholland1,2,5, Odilia Wijburg3, Simon Phipps4 and Catherine Satzke1,2,3,* 1 Infection and Immunity, Murdoch Children’s Research Institute, Royal Children's Hospital, Parkville, Victoria, Australia; 2 Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia; 3 Department of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, Victoria, Australia 4 Respiratory Immunology Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia; 5 Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom *Correspondence: [email protected] Keywords: Streptococcus pneumoniae, pneumococcus, Respiratory Syncytial Virus, Pneumonia Virus of Mice, Murine Pneumonia Virus, Influenza, co-infection ABSTRACT Streptococcus pneumoniae (the pneumococcus) is a leading cause of pneumonia in children under five years old. Co-infection by pneumococci and respiratory viruses enhances disease severity. Little is known about pneumococcal co-infections with Respiratory Syncytial Virus (RSV). Here, we developed a novel infant mouse model of co-infection using Pneumonia Virus of Mice (PVM), a murine analogue of RSV, to examine the dynamics of co-infection in the upper respiratory tract, an anatomical niche that is essential for host-to-host transmission and progression to disease.
    [Show full text]
  • Two RSV Platforms for G, F, Or G+F Proteins Vlps
    viruses Article Two RSV Platforms for G, F, or G+F Proteins VLPs Binh Ha 1, Jie E. Yang 2, Xuemin Chen 1, Samadhan J. Jadhao 1, Elizabeth R. Wright 2,3,4,* and Larry J. Anderson 1,* 1 Division of Pediatric Infectious Diseases, Emory University School of Medicine and Children’s Healthcare of Atlanta, Atlanta, GA 30322, USA; [email protected] (B.H.); [email protected] (X.C.); [email protected] (S.J.J.) 2 Department of Biochemistry, University of Wisconsin, Madison, WI 53706, USA; [email protected] 3 Cryo-Electron Microscopy Research Center, Department of Biochemistry, University of Wisconsin, Madison, WI 53706, USA 4 Morgridge Institute for Research, Madison, WI 53715, USA * Correspondence: [email protected] (E.R.W.); [email protected] (L.J.A.); Tel.: +1-608-265-0666 (E.R.W.); +1-404-712-6604 (L.J.A.); Fax: +1-608-265-4693 (E.R.W.); +1-404-727-9223 (L.J.A.) Received: 22 June 2020; Accepted: 17 August 2020; Published: 19 August 2020 Abstract: Respiratory syncytial virus (RSV) causes substantial lower respiratory tract disease in children and at-risk adults. Though there are no effective anti-viral drugs for acute disease or licensed vaccines for RSV, palivizumab prophylaxis is available for some high risk infants. To support anti-viral and vaccine development efforts, we developed an RSV virus-like particle (VLP) platform to explore the role RSV F and G protein interactions in disease pathogenesis. Since VLPs are immunogenic and a proven platform for licensed human vaccines, we also considered these VLPs as potential vaccine candidates.
    [Show full text]
  • Increased Interseasonal Respiratory Syncytial Virus (RSV)
    Montana Health Alert Network DPHHS HAN INFO SERVICE Cover Sheet DATE For LOCAL HEALTH June 11, 2021 DEPARTMENT reference only DPHHS Subject Matter Resource for SUBJECT more information regarding this HAN, contact: Increased Interseasonal Respiratory Syncytial Virus (RSV) Activity in Parts of the Southern United States Epidemiology Section 1-406-444-0273 INSTRUCTIONS For technical issues related to the HAN message contact the Emergency DISTRIBUTE AT YOUR DISCRETION. Share this information Preparedness Section with relevant SMEs or contacts (internal and external) as you at 1-406-444-0919 see fit. DPHHS Health Alert Hotline: 1-800-701-5769 DPHHS HAN Website: www.han.mt.gov REMOVE THIS COVER SHEET BEFORE REDISTRIBUTING AND REPLACE IT WITH YOUR OWN Please ensure that DPHHS is included on your HAN distribution list. [email protected] Categories of Health Alert Messages: Health Alert: conveys the highest level of importance; warrants immediate action or attention. Health Advisory: provides important information for a specific incident or situation; may not require immediate action. Health Update: provides updated information regarding an incident or situation; unlikely to require immediate action. Information Service: passes along low level priority messages that do not fit other HAN categories and are for informational purposes only. Please update your HAN contact information on the Montana Public Health Directory Montana Health Alert Network DPHHS HAN Information Sheet DATE June 11, 2021 SUBJECT Increased Interseasonal Respiratory Syncytial Virus (RSV) Activity in Parts of the Southern United States BACKGROUND RSV is an RNA virus of the genus Orthopneumovirus, family Pneumoviridae, primarily spread via respiratory droplets when a person coughs or sneezes, and through direct contact with a contaminated surface.
    [Show full text]
  • Respiratory Syncytial Virus-Specific Immunoglobulin G (Igg)
    medRxiv preprint doi: https://doi.org/10.1101/2021.08.17.21262198; this version posted August 23, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license . 1 2 Respiratory syncytial virus-specific immunoglobulin G (IgG) 3 concentrations associate with environmental and genetic factors: the 4 Factors Influencing Pediatric Asthma Study. 5 6 Esther Erdei1¶, Dara Torgerson2,3¶, Rae O'Leary4, Melissa Spear2,3, Matias Shedden1, 7 Marcia O’Leary4, Kendra Enright4, Lyle Best4, 5 8 9 1 University oF New Mexico Health Sciences Center College oF PharMacy, AlbuQuerQue, 10 NM, USA 11 2 DepartMent oF EpideMiology and Biostatistics, University oF CaliFornia San Francisco, 12 San Francisco, CA, USA 13 3 DepartMent oF HuMan Genetics, McGill University, Montreal, QC, Canada 14 4 Missouri Breaks Industries Research Inc, Eagle Butte, SD, USA 15 5 Turtle Mountain CoMMunity College, Belcourt, ND, USA 16 17 18 * Corresponding author 19 E-mail: [email protected] (LGB) 20 21 ¶These authors contributed eQually to this work. 22 1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2021.08.17.21262198; this version posted August 23, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • Taxonomy of the Order Mononegavirales: Update 2019
    Archives of Virology (2019) 164:1967–1980 https://doi.org/10.1007/s00705-019-04247-4 VIROLOGY DIVISION NEWS Taxonomy of the order Mononegavirales: update 2019 Gaya K. Amarasinghe1 · María A. Ayllón2,3 · Yīmíng Bào4 · Christopher F. Basler5 · Sina Bavari6 · Kim R. Blasdell7 · Thomas Briese8 · Paul A. Brown9 · Alexander Bukreyev10 · Anne Balkema‑Buschmann11 · Ursula J. Buchholz12 · Camila Chabi‑Jesus13 · Kartik Chandran14 · Chiara Chiapponi15 · Ian Crozier16 · Rik L. de Swart17 · Ralf G. Dietzgen18 · Olga Dolnik19 · Jan F. Drexler20 · Ralf Dürrwald21 · William G. Dundon22 · W. Paul Duprex23 · John M. Dye6 · Andrew J. Easton24 · Anthony R. Fooks25 · Pierre B. H. Formenty26 · Ron A. M. Fouchier17 · Juliana Freitas‑Astúa27 · Anthony Grifths28 · Roger Hewson29 · Masayuki Horie31 · Timothy H. Hyndman32 · Dàohóng Jiāng33 · Elliott W. Kitajima34 · Gary P. Kobinger35 · Hideki Kondō36 · Gael Kurath37 · Ivan V. Kuzmin38 · Robert A. Lamb39,40 · Antonio Lavazza15 · Benhur Lee41 · Davide Lelli15 · Eric M. Leroy42 · Jiànróng Lǐ43 · Piet Maes44 · Shin‑Yi L. Marzano45 · Ana Moreno15 · Elke Mühlberger28 · Sergey V. Netesov46 · Norbert Nowotny47,48 · Are Nylund49 · Arnfnn L. Økland49 · Gustavo Palacios6 · Bernadett Pályi50 · Janusz T. Pawęska51 · Susan L. Payne52 · Alice Prosperi15 · Pedro Luis Ramos‑González13 · Bertus K. Rima53 · Paul Rota54 · Dennis Rubbenstroth55 · Mǎng Shī30 · Peter Simmonds56 · Sophie J. Smither57 · Enrica Sozzi15 · Kirsten Spann58 · Mark D. Stenglein59 · David M. Stone60 · Ayato Takada61 · Robert B. Tesh10 · Keizō Tomonaga62 · Noël Tordo63,64 · Jonathan S. Towner65 · Bernadette van den Hoogen17 · Nikos Vasilakis10 · Victoria Wahl66 · Peter J. Walker67 · Lin‑Fa Wang68 · Anna E. Whitfeld69 · John V. Williams23 · F. Murilo Zerbini70 · Tāo Zhāng4 · Yong‑Zhen Zhang71,72 · Jens H. Kuhn73 Published online: 14 May 2019 © This is a U.S.
    [Show full text]
  • BEI Resources Product Information Sheet Catalog No. NR-48671
    Product Information Sheet for NR-48671 Human Respiratory Syncytial Virus, Growth Conditions: Host: HEp-2 cells (ATCC® CCL-23™) A/Homo sapiens/ARG/177/2006 Growth Medium: Eagle’s Minimum Essential Medium containing Earle’s Balanced Salt Solution, non-essential Catalog No. NR-48671 amino acids, 2 mM L-glutamine, 1 mM sodium pyruvate and 1500 mg/L of sodium bicarbonate supplemented with 2% For research use only. Not for use in humans. fetal bovine serum, or equivalent Infection: Cells should be 60% to 95% confluent Contributor: Incubation: 3 to 7 days at 37°C and 5% CO2 Kelly J. Henrickson, M.D., Professor, Departments of Cytopathic Effect: Cell rounding, syncytia formation, and Pediatrics and Microbiology, Medical College of Wisconsin, detachment Milwaukee, Wisconsin, USA Citation: Manufacturer: Acknowledgment for publications should read “The following BEI Resources reagent was obtained through BEI Resources, NIAID, NIH: Human Respiratory Syncytial Virus, A/Homo Product Description: sapiens/ARG/177/2006, NR-48671.” Virus Classification: Pneumoviridae, Orthopneumovirus Species: Human respiratory syncytial virus Biosafety Level: 2 Strain/Isolate: A/Homo sapiens/ARG/177/2006 Appropriate safety procedures should always be used with this Original Source: Human respiratory syncytial virus (RSV), material. Laboratory safety is discussed in the following A/Homo sapiens/ARG/177/2006 was isolated from the publication: U.S. Department of Health and Human Services, nasal cavity of a human in Buenos Aires, Argentina on June Public Health Service, Centers for Disease Control and 6, 2006.1,2 The strain was obtained by Dr. Henrickson from Prevention, and National Institutes of Health. Biosafety in Cristina Videla of the Clinical Virology Laboratory, Centro de Microbiological and Biomedical Laboratories.
    [Show full text]
  • Host Cell Restriction Factors of Paramyxoviruses and Pneumoviruses
    viruses Review Host Cell Restriction Factors of Paramyxoviruses and Pneumoviruses Rubaiyea Farrukee 1,*, Malika Ait-Goughoulte 2, Philippa M. Saunders 1 , Sarah L. Londrigan 1 and Patrick C. Reading 1,3,* 1 Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne VIC 3000, Australia; [email protected] (P.M.S.); [email protected] (S.L.L.) 2 Roche Pharma Research and Early Development, Roche Innovation Center Basel, 4070 Basel, Switzerland; [email protected] 3 WHO Collaborating Centre for Reference and Research on Influenza, Victorian Infectious Diseases Reference Laboratory at the Peter Doherty Institute for Infection and Immunity, Melbourne VIC 3000, Australia * Correspondence: [email protected] (R.F.); [email protected] (P.C.R.) Academic Editor: Sébastien Nisole Received: 13 November 2020; Accepted: 30 November 2020; Published: 2 December 2020 Abstract: The paramyxo- and pneumovirus family includes a wide range of viruses that can cause respiratory and/or systemic infections in humans and animals. The significant disease burden of these viruses is further exacerbated by the limited therapeutics that are currently available. Host cellular proteins that can antagonize or limit virus replication are therefore a promising area of research to identify candidate molecules with the potential for host-targeted therapies. Host proteins known as host cell restriction factors are constitutively expressed and/or induced in response to virus infection and include proteins from interferon-stimulated genes (ISGs). Many ISG proteins have been identified but relatively few have been characterized in detail and most studies have focused on studying their antiviral activities against particular viruses, such as influenza A viruses and human immunodeficiency virus (HIV)-1.
    [Show full text]
  • Single-Shot Vaccines Against Bovine Respiratory Syncytial Virus
    Article Single-Shot Vaccines against Bovine Respiratory Syncytial Virus (BRSV): Comparative Evaluation of Long-Term Protection after Immunization in the Presence of BRSV-Specific Maternal Antibodies Jean François Valarcher 1,* , Sara Hägglund 1, Katarina Näslund 1, Luc Jouneau 2 , Ester Malmström 1, Olivier Boulesteix 3, Anne Pinard 3, Dany Leguéré 3, Alain Deslis 3, David Gauthier 3, Catherine Dubuquoy 2, Vincent Pietralunga 2, Aude Rémot 4 , Alexander Falk 5, Ganna Shevchenko 5, Sara Bergström Lind 5, Claudia Von Brömssen 6 , Karin Vargmar 7 , Baoshan Zhang 8, Peter D. Kwong 8, María Jose Rodriguez 9, Marga Garcia Duran 9, Isabelle Schwartz-Cornil 2, Geraldine Taylor 10 and Sabine Riffault 2 1 Department of Clinical Sciences, Swedish University of Agricultural Sciences, 750 07 Uppsala, Sweden; [email protected] (S.H.); [email protected] (K.N.); [email protected] (E.M.) 2 Université Paris-Saclay, INRAE, UVSQ, VIM, 78350 Jouy-en-Josas, France; [email protected] (L.J.); [email protected] (C.D.); [email protected] (V.P.); [email protected] (I.S.-C.); [email protected] (S.R.) 3 INRAE, PFIE, 37380 Nouzilly, France; [email protected] (O.B.); [email protected] (A.P.); Citation: Valarcher, J.F.; Hägglund, [email protected] (D.L.); [email protected] (A.D.); [email protected] (D.G.) 4 INRAE, Université de Tours, ISP, 37380 Nouzilly, France; [email protected] S.; Näslund, K.; Jouneau, L.; 5 Department of Chemistry-BMC, Uppsala University, 752 37 Uppsala, Sweden; Malmström, E.; Boulesteix, O.; Pinard, [email protected] (A.F.); [email protected] (G.S.); [email protected] (S.B.L.) A.; Leguéré, D.; Deslis, A.; Gauthier, 6 Department of Energy and Technology, Swedish University of Agricultural Sciences, 750 07 Uppsala, Sweden; D.; et al.
    [Show full text]